News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Zhanna Jumadilova, MD, MBA

Articles by Zhanna Jumadilova, MD, MBA

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population

ByFadia T. Shaya, PhD, MPH,Steven Blume, MS,Anna Gu, MA,Teresa Zyczynski, PharmD, MBA, MPH,Zhanna Jumadilova, MD, MBA

July 15th 2005

Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates

ByNicole M. Nitz, PhD,Zhanna Jumadilova, MD, MBA,Theodore Darkow, PharmD,Jennifer R. Frytak, PhD,Tamara Bavendam, MD

July 15th 2005

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder

BySujata Varadharajan, MS,Zhanna Jumadilova, MD, MBA,Prafulla Girase, MS,Daniel A. Ollendorf, MPH

July 15th 2005

Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment

ByZhanna Jumadilova, MD, MBA,Teresa Zyczynski, PharmD, MBA, MPH,Barbara Paul, MD,Siva Narayanan, MS, MHS

July 15th 2005

Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin

ByEleanor M. Perfetto, PhD,Prasun Subedi, MS,Zhanna Jumadilova, MD, MBA

July 15th 2005

Latest Updated Articles

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population
Published: July 15th 2005 | Updated:
Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates
Published: July 15th 2005 | Updated:
Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder
Published: July 15th 2005 | Updated:
Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment
Published: July 15th 2005 | Updated:
Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin
Published: July 15th 2005 | Updated:

Trending on AJMC

House Republicans Block Vote on ACA Subsidy Extension

ICYMI: Highlights From the 2025 ASPC Congress on CVD Prevention

FDA Approves Rucaparib in BRCA-Mutated mCRPC

Higher BMI, IBD Linked to Hidradenitis Suppurativa Risk via Mendelian Randomization

Phase 1 RNL-186 Shows Promise for Leptomeningeal Metastases: Andrew Brenner, MD, PhD

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.